Literature DB >> 20870724

Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.

Joel Jules1, Zhenqi Shi, Jianzhong Liu, Duorong Xu, Shunqing Wang, Xu Feng.   

Abstract

Tumor necrosis factor-α (TNF) enhances osteoclast formation and activity leading to bone loss in various pathological conditions, but its precise role in osteoclastogenesis remains controversial. Although several groups showed that TNF can promote osteoclastogenesis independently of the receptor activator of NF-κB (RANK) ligand (RANKL), others demonstrated that TNF-mediated osteoclastogenesis needs permissive levels of RANKL. Here, we independently reveal that although TNF cannot stimulate osteoclastogenesis on bone slices, it can induce the formation of functional osteoclasts on bone slices in the presence of permissive levels of RANKL or from bone marrow macrophages (BMMs) pretreated by RANKL. TNF can still promote the formation of functional osteoclasts 2 days after transient RANKL pretreatment. These data have confirmed that TNF-mediated osteoclastogenesis requires priming of BMMs by RANKL. Moreover, we investigated the molecular mechanism underlying the dependence of TNF-mediated osteoclastogenesis on RANKL. RANK, the receptor for RANKL, contains an IVVY(535-538) motif that has been shown to play a vital role in osteoclastogenesis by committing BMMs to the osteoclast lineage. We show that TNF-induced osteoclastogenesis depends on RANKL to commit BMMs to the osteoclast lineage and RANKL regulates the lineage commitment through the IVVY motif. Mechanistically, the IVVY motif controls the lineage commitment by reprogramming osteoclast genes into an inducible state in which they can be activated by TNF. Our findings not only provide important mechanistic insights into the action of RANKL in TNF-mediated osteoclastogenesis but also establish that the IVVY motif may serve as an attractive therapeutic target for bone loss in various bone disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870724      PMCID: PMC2988348          DOI: 10.1074/jbc.M110.149484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

2.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Authors:  Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

Review 3.  Regulatory roles and molecular signaling of TNF family members in osteoclasts.

Authors:  Xu Feng
Journal:  Gene       Date:  2005-04-25       Impact factor: 3.688

4.  Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts.

Authors:  Y Azuma; K Kaji; R Katogi; S Takeshita; A Kudo
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

5.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Authors:  J Li; I Sarosi; X Q Yan; S Morony; C Capparelli; H L Tan; S McCabe; R Elliott; S Scully; G Van; S Kaufman; S C Juan; Y Sun; J Tarpley; L Martin; K Christensen; J McCabe; P Kostenuik; H Hsu; F Fletcher; C R Dunstan; D L Lacey; W J Boyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

6.  Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function.

Authors:  Wei Liu; Duorong Xu; Hongmei Yang; Hui Xu; Zhenqi Shi; Xuemei Cao; Sunao Takeshita; Jianzhong Liu; Michael Teale; Xu Feng
Journal:  J Biol Chem       Date:  2004-10-12       Impact factor: 5.157

Review 7.  Influence of RANKL inhibition on immune system in the treatment of bone diseases.

Authors:  Anne Fouque-Aubert; Roland Chapurlat
Journal:  Joint Bone Spine       Date:  2007-08-29       Impact factor: 4.929

8.  Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.

Authors:  Matteo M Guerrini; Cristina Sobacchi; Barbara Cassani; Mario Abinun; Sara S Kilic; Alessandra Pangrazio; Daniele Moratto; Evelina Mazzolari; Jill Clayton-Smith; Paul Orchard; Fraser P Coxon; Miep H Helfrich; Julie C Crockett; David Mellis; Ashok Vellodi; Ilhan Tezcan; Luigi D Notarangelo; Michael J Rogers; Paolo Vezzoni; Anna Villa; Annalisa Frattini
Journal:  Am J Hum Genet       Date:  2008-07       Impact factor: 11.025

9.  Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice.

Authors:  Hyunsoo Kim; Han Kyoung Choi; Ji Hye Shin; Kyung Hee Kim; Ji Young Huh; Seung Ah Lee; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Hwa Jeong Lee; Daewon Jeong; Nacksung Kim; Yongwon Choi; Soo Young Lee
Journal:  J Clin Invest       Date:  2009-03-02       Impact factor: 14.808

10.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  22 in total

Review 1.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Authors:  Joel Jules; Shunqing Wang; Zhenqi Shi; Jianzhong Liu; Shi Wei; Xu Feng
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

3.  Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.

Authors:  Yuyu Li; Zhenqi Shi; Joel Jules; Shenyuan Chen; Robert A Kesterson; Dongfeng Zhao; Ping Zhang; Xu Feng
Journal:  J Bone Miner Res       Date:  2019-08-02       Impact factor: 6.741

Review 4.  Cellular and Molecular Pathways Leading to External Root Resorption.

Authors:  A Iglesias-Linares; J K Hartsfield
Journal:  J Dent Res       Date:  2016-11-05       Impact factor: 6.116

5.  C/EBPα transcription factor is regulated by the RANK cytoplasmic 535IVVY538 motif and stimulates osteoclastogenesis more strongly than c-Fos.

Authors:  Joel Jules; Wei Chen; Xu Feng; Yi-Ping Li
Journal:  J Biol Chem       Date:  2017-11-09       Impact factor: 5.157

6.  C/EBPα and PU.1 exhibit different responses to RANK signaling for osteoclastogenesis.

Authors:  Joel Jules; Yi-Ping Li; Wei Chen
Journal:  Bone       Date:  2017-10-12       Impact factor: 4.398

7.  Notch signaling promotes osteoclast maturation and resorptive activity.

Authors:  Jason W Ashley; Jaimo Ahn; Kurt D Hankenson
Journal:  J Cell Biochem       Date:  2015-11       Impact factor: 4.429

8.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

Authors:  Anandi Sawant; Jessy Deshane; Joel Jules; Carnella M Lee; Brittney A Harris; Xu Feng; Selvarangan Ponnazhagan
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

9.  CCAAT/Enhancer-binding Protein α (C/EBPα) Is Important for Osteoclast Differentiation and Activity.

Authors:  Joel Jules; Wei Chen; Xu Feng; Yi-Ping Li
Journal:  J Biol Chem       Date:  2016-04-20       Impact factor: 5.157

10.  Interaction of Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) and Vav3 in the Receptor Activator of Nuclear Factor κB (RANK) Signaling Complex Enhances Osteoclastogenesis.

Authors:  Jiyeon Yu; Hyeongseok Yun; Bongjin Shin; Yongjin Kim; Eui-Soon Park; Seunga Choi; Jungeun Yu; Dulshara Sachini Amarasekara; Sumi Kim; Jun-Ichiro Inoue; Matthew C Walsh; Yongwon Choi; Masamichi Takami; Jaerang Rho
Journal:  J Biol Chem       Date:  2016-08-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.